Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

[EX Q]: Paragraph: CES is allowing space for sex tech companies as a one-year trial. At the show, such companies were scattered throughout the health and wellness section, near startups pitching fitness trackers and infrared saunas. Lora DiCarlo, a startup that pushed for changes after organizers revoked its award, showed off its Osé robotic “personal massager.” It’s one of a dozen companies at the show focused on vibrators, lube dispensers and other sex tech products. Founders of these startups say their products are about empowerment and wellness for women, something they say has often been overlooked in tech. The historically male-dominated tech trade show has received criticism in past years for having an all-male lineup of speakers and for previously allowing scantily clad “booth babes,” fostering a “boys’ club” reputation. Besides allowing sex tech, CES organizers brought in an official “equality partner,” The Female Quotient, to help ensure gender diversity. The Female Quotient, which trains companies in equality practices, will hold a conference for women during the four-day show, which opened Tuesday. “It’s been a process,” said Gary Shapiro, the head of the Consumer Technology Association, which puts on CES. It’s been a longer process for many sex tech companies to convince investors that they are part of a growing trend that has enough customers. Much of the push has come from the startups’ female founders and from younger consumers who talk more openly about sexuality. As with other technologies, some exhibitors including Lora DiCarlo had prominent booths at CES, while others such as the wearable vibrator company Crave were tucked away. Crave’s exhibit included a camper with a “Build-a-Vibe-Workshop,” where attendees could get an engraved vibrator to wear around their neck. Sex tech has existed in some form for decades. But the gates really began to open in 2016, said Andrea Barrica, founder of sex education site O.school. That year, several other “fem tech” companies made progress in areas such as menstruation and menopause. Those paved the way for sex tech to grow and get investors interested. “Larger institutions are starting to take note, all the way from VC firms to large Fortune 100 companies,” said Barrica, who recently published the book “Sextech Revolution: The Future of Sexual Wellness.” Large institutions like CES had no choice but to look at sex tech, she said. The journey hasn’t been easy. Sex tech founders, many of them women, recount being turned down by dozens of investors. They faced decency arguments and entrenched corporate standards that equated them with porn. But investors are becoming more receptive, said Cindy Gallop, a former advertising executive turned sex tech entrepreneur and founder of the website MakeLoveNotPorn. “It’s entirely because of our refusal to allow the business world to put us down,” she said. Founders insist that their devices — ranging from vibrators to lube dispensers to accessories — have effects outside the bedroom. “Sexual health and wellness is health and wellness,” said Lora DiCarlo, CEO and founder of the company of the same name. “It does way more than just pleasure. It’s immediately connected to stress relief, to better sleep, to empowerment and confidence.” DiCarlo’s $290 Osé device has gotten $3 million worth of advance sales, bolstered in part by the attention it received after CES organizers overturned a decision by an independent panel of judges to give the vibrator a prestigious Innovation Honoree Award in the robotics and drone category. The organizers, CTA, told the company it reserved the right to rescind awards for devices deemed “immoral, obscene, indecent, profane or not in keeping with CTA’s image.” DiCarlo and other female founders pushed back for banning them but allowing humanoid sex robots meant to serve men the previous year. Following criticism, CES organizers ultimately  reinstated the award and apologized. A few months later, the show announced policy changes such as a dress code to prevent skimpy outfits and new “Innovation for All” sessions with senior diversity officials. Osé began shipping to customers this month. DiCarlo said the company is planning to introduce new devices, including less expensive options. Sex tech companies still face major barriers to growth. Polly Rodriguez, CEO of sexual wellness company Unbound, said the company is profitable and customers are more open about buying products than they once were. But she said she still faces roadblocks advertising on social media, and many traditional investors snub the company. “Things are better, but there’s just still this genuine fear of female sexuality more broadly within the institutional side of technology,” she said. And while Gallop offered to speak at CES, conference organizers declined, saying sex tech was not a part of its conference programming. ___ AP Business Writer Joseph Pisani contributed to this report. ___ AP’s CES coverage: https://apnews.com/Consumerelectronics Claim: Sex tech from women-led startups pops up at CES gadget show.
[EX A]: Sex tech is gracing the CES gadget show in Las Vegas this week, a year after organizers took fire for revoking an innovation award to a sex device company led by a female founder.

[EX Q]: Paragraph: Mays, speaking to a TV critics’ meeting Friday, pointed to several bottles she had filled with her tap water and challenged the room to taste or even smell it. There were no immediate takers. The activist, who said the battle over water safety continues, is among the residents portrayed in Lifetime’s movie titled “Flint,” debuting Oct. 28. Mays is played by Marin Ireland, who co-stars with Betsy Brandt, Jill Scott and Queen Latifah. Executive producer Neil Meron said the film is intended to spotlight what happened in Flint, including how a united community and “the voice of the people” can force officials to act. Mays said there have been successes, including the outcome of a lawsuit to get half of the service lines replaced, although not the main lines or interior plumbing. “So one of the things we hope come out of this is to let people know it’s still not over. It’s not even close to over,” she said. The movie is intended to honor Flint victims by telling the story “that even in a poor, broken, poisoned town, we banded together, and we fought. We fought, and we win.” In 2014, a switch of Flint’s water source and failure to add corrosion-reducing phosphates allowed lead from old pipes to leach into the water. Elevated levels of lead, a neurotoxin, were detected in children, and 12 people died in a Legionnaires’ disease outbreak that experts suspect was linked to the improperly treated water. An ongoing investigation has led to charges against 13 current or former government officials, including two managers who Republican Gov. Rick Snyder appointed to run the city. Last January, state officials said Flint’s water system no longer has lead levels exceeding the federal limit. The announcement was promptly met by skepticism from some residents, Mays among them, maintaining the system still contains lead and continues to cause illness. Brandt, the former “Breaking Bad” star who’s a native of Bay City, Michigan, not far from Flint, said the person she portrays, LeeAnne Walters, was among those driven to act when authorities failed to heed complaints about their children becoming ill. “As a mom, it just shakes you, because there’s some things that we just should be able to count on,” Brandt said. Claim: Lifetime movie ‘Flint’ dramatizes city’s water crisis.
[EX A]: Melissa Mays, a resident of Flint, Michigan, came armed to discuss the city’s tainted water crisis and a new Lifetime TV movie dramatizing it.

[EX Q]: Paragraph: It’s too early to discuss how much one of these experimental drugs might cost. But the article could have reported something about the estimated costs of currently caring for these patients. It’s also worth noting that if a drug is ever approved, it will cost Medicare a bundle. In the story’s descriptions of “promising” drugs from Biogen, Merck and Lilly, there is essentially zero quantification data. There needed to be some, even in a wrap-up or trend article such as this. The story did not cover harms. A problem with these drugs is that they can cause amyloid-related imaging abnormalities (ARIAs), which are findings on brain scans that indicate swelling and small hemorrhages in portions of the brain. These were the most frequent adverse events in the Biogen study and occurred in a lot of people, especially at the higher doses. Overall, the story did a good job explaining why several major pharmaceutical firms think there is still hope for an anti-amyloid strategy for Alzheimer’s disease. As noted in the summary, it might have been useful for the article to have stated earlier–and perhaps more forcefully–that despite the confidence drug developers appear to have in the amyloid hypothesis, the scientific jury is still out. And a discussion of competing hypotheses would have been useful to add, too. No mongering here. The story had no independent sources. It also didn’t disclose the conflict of interest of Dr. Paul Aisen, who has received money from multiple drug companies, including the ones discussed in this piece. The story adequately compares alternatives and discusses the overall lack of any effective medication for Alzheimer’s disease. As noted above, however, a discussion of competing hypotheses about the origins of the disease, along with related potential treatment strategies, would have been useful to include. The article makes pretty darn clear that there will be a) no final answers to the amyloid hypothesis debate any time soon; and b) the advent of a successful anti-amyloid drug that helps those with Alzheimer’s is not close at hand. As noted earlier, this was not a “breaking news” story, but a round up of sorts of what’s happened since the Lilly drug trial for solanezumab reported negative results. But there is news-like information here about the optimism of the companies still working the amyloid hypothesis. Whether a high level of optimism is warranted or not is a good question, but the article could at least inform a healthy discussion. There appears to be original reporting and perhaps use of one (at least) news release. Claim: Why Biogen is breathing a sigh of relief with the latest Alzheimer’s data
[EX A]:
This STAT story is a contextual view of not only the status of doomed scientific efforts so far to delay or halt Alzheimer’s dementia at its biological sources, but also of Big Pharma’s persistence at chasing an anti-amyloid cure. The reporting makes the case that in the opinion of credible researchers, the reason for failures to date is that Lilly’s drug and others didn’t get to the amyloid when and where it needed to, not that amyloid isn’t the culprit. Although the article could have made the point sooner, it does state clearly that there is still no scientific consensus that amyloid plaque even IS the right target. The story would have been greatly strengthened by giving some quantitative data about the various studies cited, as well as the inclusion of an independent expert. Given the devastating magnitude of Alzheimer’s disease, reports like the one in STAT are intensely searched for and read by not only those with personal knowledge of the disease, but by the worried well.